ERK5 is a critical mediator of inflammation-driven cancer

  • Finegan K
  • Perez-Madrigal D
  • Hitchin J
 et al. 
  • 25


    Mendeley users who have this article in their library.
  • 18


    Citations of this article.


Chronic inflammation is a hallmark of many cancers, yet the pathogenic mechanisms that distinguish cancer-associated inflammation from benign persistent inflammation are still mainly unclear. Here, we report that the protein kinase ERK5 controls the expression of a specific subset of inflammatory mediators in the mouse epidermis, which triggers the recruitment of inflammatory cells needed to support skin carcinogenesis. Accordingly, inactivation of ERK5 in keratinocytes prevents inflammation-driven tumorigenesis in this model. In addition, we found that anti-ERK5 therapy cooperates synergistically with existing antimitotic regimens, enabling efficacy of subtherapeutic doses. Collectively, our findings identified ERK5 as a mediator of cancer-associated inflammation in the setting of epidermal carcinogenesis. Considering that ERK5 is expressed in almost all tumor types, our findings suggest that targeting tumor-associated inflammation via anti-ERK5 therapy may have broad implications for the treatment of human tumors.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • allan jordanCancer Research UK Manchester Institute

  • Katherine G. Finegan

  • Diana Perez-Madrigal

  • James R. Hitchin

  • Clare C. Davies

  • Cathy Tournier

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free